|Publication date:||November 09 2020|
For a newly created start-up in the field of Treg targeted therapies for the treatment of autoimmune diseases, we are currently looking for a CEO. This organisation is focusing on the development of a new class of biologics (bispecific antibodies, immunocytokines etc.) to stimulate and activate Tregs in patients suffering from autoimmune diseases with the aim to restore the immune balance. This is done through combining the efforts of several top academic labs, each pursuing their own pathways.
As CEO you will be responsible to successfully grow this new biotherapeutics business by setting vision, strategy and direction, building connections with VCs, pharma partners, PIs and other stakeholders, and raising a Series A investment round in mid 2022 in strong collaboration with the organisation’s CSO.
Also you will bring a balance of business and commercial skills and scientific understanding. You do not need to be a specific scientific expert in immunology but need to be able to get up to speed with the science and articulate the vision of the organisation both internally and externally.
In short, as the ideal candidate you are an exceptional CCO / COO / CBO / Corporate BD person with high potential and ready to step-up, with significant experience in the life sciences industry.
You will recognise yourself in the following profile:
This is demonstrated and illustrated by the following skills and abilities:
If driving an ambitious, scientifically strong biotech start-up to great success all the while partnering with an inspiring CSO is your thing, do not hesitate and contact me.
On offer is a change of a lifetime with a package to match!
If you are interested in this job, or in similar ones, please feel free to contact me directly.
Martin van der Velden